Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-Label, Multicenter Phase I/II Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of FG-B901 Injection as Monotherapy and in Combination With Standard or Investigator-Determined Chemotherapy in Subjects With Unresectable Locally Advanced or Metastatic Solid Tumors

NCT07623707 is registered in ClinicalTrials.gov with FutureGen Biopharmaceutical (Beijing) Co., Ltd as lead sponsor.

NCT NCT07623707
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07623707 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-Label, Multicenter Phase I/II Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of FG-B901 Injection as Monotherapy and in Combination With Standard or Investigator-Determined Chemotherapy in Subjects With Unresectable Locally Advanced or Metastatic Solid Tumors
Lead sponsor
FutureGen Biopharmaceutical (Beijing) Co., Ltd
Phase
Phase 1/2
Overall status
Not yet recruiting
Start date
July 31, 2026
Completion date
July 31, 2029
Enrollment
264 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

solid tumor